Invitation Homes Inc. Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Invitation Homes Inc. Common Stock trades at $26.54 (market cap $15.70B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Invitation Homes Inc. Common Stock is far larger — about 10.6× uniQure N.V. Ordinary Shares's market cap, and Invitation Homes Inc. Common Stock pays a 4.51% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invitation Homes Inc. Common Stock for 0 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| INVH | QURE | |
|---|---|---|
Market Cap | $15.70B | $1.48B |
Volume | 4,685,416 | 2,488,780 |
Sector | Real Estate | Health |
52-Week High | $30.59 | $70.59 |
52-Week Low | $24.39 | $9.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $24.16B | $728.62M |
Dividend Yield | 4.51% | — |
Signals from Pluang's Aura AI — not financial advice
INVH trades at $26.59, down 0.41% on the day, with neutral technical signals and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue growth from $2.73B in 2025 to $2.9B projected for 2026 supports a solid profit margin expansion to 23.13%. Analyst consensus remains bullish with a $31.67 price target, representing 19% upside potential from current levels.
The investment case centers on INVH's consistent earnings outperformance and robust single-family rental demand, though rising interest rates pose headwinds. With 56% of analysts recommending Buy and institutional accumulation continuing, the stock offers value at current levels despite technical consolidation. Key risks include interest rate sensitivity and regulatory changes affecting institutional homebuying.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Invitation Homes Inc. is a real estate investment trust that acquires, renovates, and leases single-family rental homes across roughly 19 US markets concentrated in Western and Southeastern US. It manages its portfolio through a pod-based local operating model supported by a maintenance technology platform.
Read more on INVH →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →